Commentary: Progress, Issues, and Implications of Prodromal Research: An Inside View

Schizophrenia Bulletin

Volumn 29, Issue 4, 2003, Pages 851-858

  McGlashan, Thomas H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE;

ANXIETY; BEHAVIOR THERAPY; CLINICAL RESEARCH; COGNITION; CONFERENCE PAPER; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MENTAL DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRODROMAL SCHIZOPHRENIA; PROSPECTIVE STUDY; PSYCHOSIS; RESOURCE ALLOCATION; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 0842321877     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007051     Document Type: Conference Paper

References (32)

1. Cannon, T.D.; van Erp, T.G.M.; Bearden, C.E.; Loewy, R.; Thompson, P.; Toga, A.W.; Huttunen, M.O.; Keshavan, M.; Seidman, L.J.; and Tsuang, M.T. Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions. Schizophrenia Bulletin, 29(4):653-669, 2003.
2. Corcoran, C.; Walker, E.; Huot, R.; Mittal, V.; Tessner, K.; and Kestler, L. The stress cascade and schizophrenia: Etiology and onset. Schizophrenia Bulletin, 29(4):671-692, 2003.
3. Comblatt, B.A.; Lencz, T.; Smith, C.W.; Correll, C.U.; Auther, A.M.; and Nakayama, E. The schizophrenia prodrome revisited: A neurodevelopmental perspective. Schizophrenia Bulletin, 29(4):633-651, 2003.
4. Häfner, H.; Maurer, K.; Löffler, W.; an der Heiden, W.; Könnecke, R.; and Hambrecht, M. Onset and prodromal phase as determinants of the course. In: Gattaz, W.F., and Häfner, H., eds. Search for the Causes of Schizophrenia: Balance of the Century. Vol. IV. Berlin, Germany: Springer, 1999. pp. 1-24.
5. Heinssen, R.K.; Cuthbert, B.N.; Breiling, J.; Colpe, L.; and Dolan-Sewell, R. Overcoming Barriers to Research in Early Serious Mental Illness: Issues for Future Collaboration. Schizophrenia Bulletin, 29(4):737-745, 2003.
6. Johannessen, J.O.; McGlashan, T.H.; Larsen, T.K.; Homeland, M.; Joa, I.; Mardal, S.; Kvebæk; Friis, S.; Melle, I.; Opjordsmoen, S.; Simonsen, E.; Ulrik, H.; and Vaglum, P. Early detection strategies for untreated first-episode psychosis. Schizophrenia Research, 51:39-46, 2001.
7. Kane, J.M.; Krystal, J.; and Correll, C.U. Treatment models and designs for intervention research during the psychotic prodrome. Schizophrenia Bulletin, 29(4):747-756, 2003.
8. Keshavan, M.S.; Haas, G.; Miewald, J.; Montrose, D.M.; Reddy, R.; Schooler, N.R.; and Sweeney, J.A. Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses. Schizophrenia Bulletin, 29(4):757-769, 2003.
9. Klosterkötter, J.; Helmich, M.; Steinmeyer, E.M.; and Schultze-Lutter, F. Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry, 58:158-164, 2001.
10. Larsen, T.K.; McGlashan, T.H.; Johannessen, J.O.; Friis, S.; Guldberg, C.; Haahr, U.; Horneland, M.; Melle, I.; Moe, L.C.; Opjordsmoen, S.; Simonsen, E.; and Vaglum, P. Shortened duration of untreated first episode of psychosis: Changes in patient characteristics at treatment. American Journal of Psychiatry, 158:1917-1919, 2001.
11. Lencz, T.; Smith, C.W.; Auther, A.M.; Correll, C.U.; and Cornblatt, B.A. The assessment of "prodromal schizophrenia": Unresolved issues and future directions. Schizophrenia Bulletin, 29(4):717-728, 2003.
12. Maier, W.; Cornblatt, B.A.; and Merikangas, K. Transition to schizophrenia and related disorders: Toward a taxonomy of risk. Schizophrenia Bulletin, 29(4):693-701, 2003.
13. McGlashan, T.H. Early detection and intervention in schizophrenia: Editor's introduction. Schizophrenia Bulletin, 22(2):197-199, 1996.
14. McGlashan, T.H.; Miller, T.J.; Woods, S.W.; Hoffman, R.E.; and Davidson, L. Instrument for the assessment of prodromal symptoms and states. In: Miller, T.J. et al, eds. Early Intervention in Psychotic Disorders. The Netherlands: Kluwer Academic Publishers, 2001. pp. 135-149.
15. McGlashan, T.H.; Zipursky, R.B.; Perkins, D.; Addington, J.; Miller, T.J.; Woods, S.W.; Hawkins, K.A.; Hoffman, R.; Lindborg, S.; Tohen, M.; and Breier, A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research, 61:19-30, 2003a.
16. McGlashan, T.H.; Zipursky, R.B.; Perkins, D.O.; Addington, J.; Woods, S.W.; Miller, T.J.; Lindborg, E.; Marquez, E.; Hawkins, K.; Hoffman, R.E.; Tohen, M.; and Breier, A. Olanzapine versus placebo treatment of the schizophrenic prodrome: One-year results. Poster presentation at the International Congress of Schizophrenia Research, Colorado Springs, CO, April-May 2003b.
17. McGorry, P.D.; Yung, A.R.; and Phillips L.J. The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophrenia Bulletin, 29(4):771-790, 2003.
18. McGorry, P.D.; Yung, A.R.; Phillips, L.J.; Yuen, H.P.; Francey, S.; Cosgrave, E.M.; Germano, D.; Bravin, J.; McDonald, T.; Blair, A.; Adlard, S.; and Jackson, H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59(10):921-928, 2002.
19. Miller, T.J.; McGlashan, T.H.; Rosen, J.L.; Cadenhead, K.; Ventura J.; McFarlane, W.; Perkins, D.O.; Pearlson, G.D.; and Woods, S.W. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin, 29(4):703-715, 2003a.
20. Miller, T.J.; McGlashan, T.H.; Rosen, J.L.; Somjee, L.; Markovich, P.J.; Stein, K.; and Woods, S.W. Prospective diagnosis of the prodrome for schizophrenia: Preliminary evidence of interrater reliability and predictive validity using operational criteria and a structured interview. American Journal of Psychiatry, 159:863-865, 2002.
21. Miller, T.J.; McGlashan, T.H.; Woods, S.W.; Stein, K.; Driesen, N.; Corcoran, C.M.; Hoffman, R.; and Davidson, L. Symptoms assessment in schizophrenic prodromal states. Psychiatric Quarterly, 70:273-287, 1999.
22. Miller, T.J.; Zipursky, R.B.; Perkins, D.; Addington, J.; Woods, S.W.; Hawkins, K.A.; Hoffman, R.; Preda, A.; Epstein, I.; Addington, D.; Lindborg, S. ; Marquez, E.; Tohen, M.; Breier, A.; and McGlashan, T.H. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research, 61:19-30, 2003b.
23. Mojtabai, R.; Malaspina, D.; and Susser, E. The concept of population prevention: Application to schizophrenia. Schizophrenia Bulletin, 29(4):791-801, 2003.
24. Pantelis, C.; Velakoulis, D.; McGorry, P.D.; Wood, S.J.; Suckling, J.; Phillips, L.J.; Yung, A.R.; Bullmore, E.T.; Brewer, W.; Soulsby, B., et al. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. The Lancet, 361:281-288, 2003.
25. Rosen, J.L.; Woods, S.W.; Miller, T.J.; and McGlashan, T.H. Prospective observations of emerging psychosis. Journal of Nervous and Mental Disease, 190:133-141, 2002.
26. Ross, R.G.; Schaeffer, J.; Compagnon, N.; Heinlein, S.; Beresford, C.; and Farley, G. Creating school-age versions of semi-structured interviews for the prodrome to schizophrenia: Lessons from case reviews. Schizophrenia Bulletin, 29(4):729-735, 2003.
27. Seidman, L.J.; Pantelis, C.; Keshavan, M.S.; Faraone, S.V.; Goldstein, J.M.; Horton, N.J.; Makris, N.; Falkai, P.; Caviness, V.S.; and Tsuang, M.T. A review and a new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: An MRI morphometric family study of the parahippocampal gyrus. Schizophrenia Bulletin, 29(4):803-830, 2003.
28. Wood, S.J.; Berger, G.; Velakoulis, D.; Phillips, L.J.; McGorry, P.D.; Yung, A.R.; Desmond, P.; and Pantelis, C. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophrenia Bulletin, 29(4):831-843, 2003.
29. Woods, S.W.; Breier, A.; Zipursky, R.B.; Perkins, D.O.; Addington, J.; Miller, T.J.; Hawkins, K.A.; Marquez, E.; Lindborg, S.R.; Tohen, M.; and McGlashan, T.H. Randomed trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry, 54(4):453-464, 2003.
30. Yung, A.R., and McGorry, P.D. The prodromal phase of first-episode psychosis. Schizophrenia Bulletin, 22(2):353-370, 1996.
31. Yung, A.R.; McGorry, P.D.; McFarlane, C.A.; Jackson, H.J.; Patton, G.C.; and Rakkar, A. Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22:283-303, 1996.
32. Yung, A.R.; Phillips, L.J.; Yuen, H.P.; Francey, S.M.; McFarlane, C.A.; Hallgren, M.; and McGorry, P.D. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophrenia Research, 60:21-32, 2003.